Biomarkers and mechanisms of asthma remission following treatment with mepolizumab in adults with severe asthma – 3TR ABC

niversity of Leicester0 个研究点目标入组 150 人开始时间: 2023年5月12日最近更新: 2024年8月26日

适应症

试验速览

暂无简介。

•1. Adults (=18 years old)
•2. Clinical decision to initiate mepolizumab for severe asthma after meeting licensing, local and national guidelines
•3. Be able to give valid written consent. Participants should have a reasonable understanding of the English language (assessed by the research team)
•4. Compliant with study procedures and study visits

•1. Known hypersensitivity to the active substance of mepolizumab or any of the excipients
•2. Participation in an interventional clinical trial within 3 months of visit 1 or receipt of any investigational medicinal product within 3 months or 5 half-lives. Participation in other observational studies is acceptable if in the view of the investigator it will not impact the study outcomes
•3. Other clinically significant medical disease or uncontrolled concomitant disease that is likely, in the opinion of the investigator, to require a change in therapy or impact the ability to participate in the study

发起方

niversity of Leicester